Denali Therapeutics Stock Target Price and Analyst Consensus
| DNLI Stock | USD 23.58 0.17 0.73% |
The current analyst and expert consensus on Denali Therapeutics is Strong Buy, with 13 strong buy opinions. The current projected Denali Therapeutics target price consensus is 39.73 with 18 analyst opinions. Check out Macroaxis Advice on Denali Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.The most common way Denali Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Denali Therapeutics executives and customers to further validate their buy or sell advice. Denali Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Denali Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 4.1956.
Lowest Forecast 36.16 | Highest Forecast 44.1 | Target Price 39.73 |
Denali |
It's important to approach Denali Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Denali Therapeutics Target Price Consensus
Denali target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Denali Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 18 | Strong Buy |
Most Denali analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Denali stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Denali Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDenali Therapeutics Target Price Projection
Denali Therapeutics' current and average target prices are 23.58 and 39.73, respectively. The current price of Denali Therapeutics is the price at which Denali Therapeutics is currently trading. On the other hand, Denali Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Denali Therapeutics Market Quote on 30th of January 2025
Target Price
Analyst Consensus On Denali Therapeutics Target Price
Denali Therapeutics Analyst Ratings
Denali Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Denali Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Denali Therapeutics' financials, market performance, and future outlook by experienced professionals. Denali Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Denali Therapeutics price targets
Denali Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Denali Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Denali Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Denali Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Denali Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Denali Therapeutics is a key component of Denali Therapeutics valuation and have some predictive power on the future returns of a Denali Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Power Assets Invested over 300 shares | |
 | Dividend Beast Invested over 50 shares | |
 | Impulse Invested over 100 shares | |
 | Cash Cows Invested few shares | |
 | Banking Invested over 30 shares | |
 | Momentum Invested over 60 shares | |
 | Warren Buffett Holdings Invested few shares | |
 | Investor Favorites Invested over 300 shares | |
 | Business Services Invested few shares | |
 | FinTech Invested over 60 shares | |
 | Driverless Cars Invested over 50 shares | |
 | Automobiles and Trucks Invested over 300 shares | |
 | Manufacturing Invested over 30 shares | |
 | ESG Investing Invested few shares |
Check out Macroaxis Advice on Denali Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.